lurasidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 23 Diseases   12 Trials   12 Trials   1381 News 


«12...4567891011121314...1516»
  • ||||||||||  lurasidone oral / Generic mfg.
    [VIRTUAL] Beneficial Effects of Chronic Lurasidone Treatment in StressBased Models of Psychiatric Disorder () -  Mar 7, 2021 - Abstract #CINP2021CINP_120;    
    As adjunctive therapy, lurasidone, bupropione, and olanzapine/fluoxetine combination were superior to placebo. In summary, our studies provide new insights on the mechanism of action of lurasidone in the context of stress-related dysfunction, suggesting that it may promote adaptive mechanisms that are crucial for the ability to modulate different pathological domains associated with psychiatric disorders.
  • ||||||||||  lurasidone oral / Generic mfg.
    Journal:  Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. (Pubmed Central) -  Mar 6, 2021   
    Specific manic symptoms were found to be linked to sleep disturbance (characterized as a "bridge" symptom), which in turn linked the manic and depressive symptom clusters. The presence (vs. absence) of the specific manic symptoms we identified moderated the antidepressant and antimanic effects of lurasidone in the treatment of MDD with mixed (subthreshold hypomanic) features.
  • ||||||||||  SEP-363856 / Sumitomo Dainippon
    [VIRTUAL] The Safety Profile of the TAAR1 Agonist, SEP-363856, is Distinct from Atypical Antipsychotics () -  Mar 1, 2021 - Abstract #SIRS2021SIRS_728;    
    These results support characterization of SEP-363856 as a novel class for the treatment of schizophrenia. This database-driven approach represents a new way to summarize adverse events by cumulative burden of class-specific risks and will serve as a helpful tool to evaluate novel classes of drugs with otherwise uncharacterized safety profiles.
  • ||||||||||  SEP-363856 / Sumitomo Dainippon
    [VIRTUAL] The Safety Profile of the TAAR1 Agonist, SEP-363856, is Distinct from Atypical Antipsychotics () -  Mar 1, 2021 - Abstract #SIRS2021SIRS_602;    
    These results support characterization of SEP-363856 as a novel class for the treatment of schizophrenia. This database-driven approach represents a new way to summarize adverse events by cumulative burden of class-specific risks and will serve as a helpful tool to evaluate novel classes of drugs with otherwise uncharacterized safety profiles.
  • ||||||||||  lurasidone / Generic mfg.
    Enrollment change:  Lurasidone Effects on Tissue Glutamate in Schizophrenia (clinicaltrials.gov) -  Mar 1, 2021   
    P4,  N=35, Completed, 
    This questions whether changing an AP because of weight gain is a sensible strategy. N=50 --> 35
  • ||||||||||  lurasidone / Generic mfg.
    Enrollment open, Trial initiation date:  A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression (clinicaltrials.gov) -  Feb 10, 2021   
    P3,  N=362, Recruiting, 
    While still investigational, the preliminary evidence presented here gives reason to hope that lurasidone could possibly be an effective option in Tourette syndrome, warranting further investigation of its potential benefits in neurodevelopmental conditions. Not yet recruiting --> Recruiting | Initiation date: Jun 2020 --> Dec 2020
  • ||||||||||  lurasidone oral / Generic mfg.
    Clinical, Journal:  Up-to-date Expert Opinion on the safety of recently developed antipsychotics. (Pubmed Central) -  Jan 28, 2021   
    Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO, and the Cochrane Library from inception until March 2020, combining free terms and MESH headings for the topics of TGA and recently developed and/or marketed antipsychotics as following: ((safety OR adverse events OR side effects) AND ((brexpiprazole OR cariprazine OR inhaled loxapine OR lumateperone (ITI-007) OR lurasidone OR pimavanserin OR roluperidone (MIN-101) OR transdermal patch asenapine))...Overall, newer antipsychotics display a good safety profile, with a well-demonstrated lower metabolic liability compared to second-generation antipsychotics. Furthermore, TGA appear to specifically target negative symptomatology and improving cognitive domains.
  • ||||||||||  risperidone / Generic mfg., lurasidone oral / Generic mfg.
    Journal:  Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. (Pubmed Central) -  Jan 14, 2021   
    In addition, this study demonstrated that 80 mg/d lurasidone, an effective and tolerable dose for non-TRS patients, was also effective in TRS patients but required longer duration of treatment. Direct comparison of lurasidone with clozapine in TRS patients is indicated.
  • ||||||||||  risperidone / Generic mfg., lurasidone oral / Generic mfg., ziprasidone / Generic mfg.
    [VIRTUAL] Incidence of suicidal related behaviors among the PTSD population using antipsychotics () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3366;    
    The results of this study suggest that certain antipsychotics may put individuals within the PTSD population at an increased risk of SRBs, and that careful consideration may need to be taken when prescribed. We hope our study provides a critical gateway into the relationship of certain antipsychotics and suicide risk.
  • ||||||||||  lurasidone oral / Generic mfg.
    Clinical, Journal:  Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. (Pubmed Central) -  Dec 22, 2020   
    We hope our study provides a critical gateway into the relationship of certain antipsychotics and suicide risk. Findings of this post-hoc analysis based on a placebo-controlled trial in patients with schizophrenia suggest that baseline CRP level combined with measures of metabolic risk significantly moderated the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment. Our findings underscore the importance of maintaining a low metabolic risk profile in patients with schizophrenia.
  • ||||||||||  lurasidone oral / Generic mfg., quetiapine / Generic mfg.
    Clinical, Journal:  Comparison of Lurasidone Versus Quetiapine for the Treatment of Delirium in Critically Ill Patients. (Pubmed Central) -  Dec 19, 2020   
    Additionally, the incidence of QTc prolongation between agents does not appear to be different. Future randomized trials should evaluate dose escalation schemes and a larger proportion of patients to evaluate differences in mortality, efficacy, and life-threatening arrhythmias associated with atypical antipsychotic use.
  • ||||||||||  Saphris (asenapine) / Lundbeck, Meiji Seika, AbbVie
    Retrospective data, Review, Journal:  Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. (Pubmed Central) -  Dec 18, 2020   
    To efficaciously and efficiently tackle the problem of AIWG in clinical practice and trials, people at high risk need to be identified by predictive tools enabling the clinician to offer tailored adjunctive therapies (medication and/or lifestyle interventions). Most importantly, weight and metabolic monitoring ought to be consequently implemented in clinical routine in the treatment of any patient with any diagnosis when antipsychotics are prescribed.
  • ||||||||||  bromocriptine / Generic mfg., lurasidone oral / Generic mfg.
    [VIRTUAL] FACIAL DYSTONIA MASQUERADING AS ANGIOEDEMA () -  Nov 21, 2020 - Abstract #ACAAI2020ACAAI_658;    
    He had resolution of symptoms with no further episodes, and was discharged with follow up with his psychiatrist.Discussion We present a case of facial dystonia likely secondary to atypical antipsychotic use where tongue protrusion was initially managed as histaminergic angioedema. This case highlights the importance of identifying true angioedema in contrast to disorders mimicking angioedema.
  • ||||||||||  quetiapine extended-release / Generic mfg., lurasidone oral / Generic mfg.
    Clinical, Journal, HEOR:  Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. (Pubmed Central) -  Nov 14, 2020   
    The current study offers a promising strategy to overcome poor solubility/dissolution and be able to eliminate gelation of amorphous materials by coamorphization and complexation. The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view.
  • ||||||||||  lurasidone / Generic mfg.
    Enrollment open, Trial initiation date:  The Safety and Effectiveness of Latuda (clinicaltrials.gov) -  Nov 4, 2020   
    P=N/A,  N=3000, Recruiting, 
    The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. Not yet recruiting --> Recruiting | Initiation date: Jun 2020 --> Dec 2020
  • ||||||||||  risperidone / Generic mfg., Egis, lurasidone oral / Generic mfg.
    Clinical, Journal:  Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. (Pubmed Central) -  Nov 3, 2020   
    P3
    In this 6-month extension study, lurasidone treatment was generally well-tolerated and associated with minimal effects on weight, metabolic parameters, and prolactin levels. Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone.
  • ||||||||||  Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
    Trial completion date, Trial primary completion date:  SBD-ASIB: NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (clinicaltrials.gov) -  Nov 2, 2020   
    P2/3,  N=72, Recruiting, 
    Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Aug 2021
  • ||||||||||  Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
    Biomarker, Trial completion date, Trial primary completion date:  NRX-GLX: NRX101 Glx Biomarker Validation Study (clinicaltrials.gov) -  Oct 30, 2020   
    P2/3,  N=24, Active, not recruiting, 
    Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Aug 2021 Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
    Trial completion date, Trial primary completion date:  MBD: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation (clinicaltrials.gov) -  Oct 30, 2020   
    P2/3,  N=150, Not yet recruiting, 
    Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2019 --> Mar 2022